Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Viyash Scientific ( (IN:VIYASH) ) has shared an announcement.
Viyash Scientific Limited’s board has appointed Amit Jain and Abhiroop Jayanthi as additional non-executive, non-independent directors, both representing Carlyle, effective April 22, 2026, subject to shareholder approval. The move strengthens Carlyle’s representation on the board and may influence the company’s strategic direction and governance through enhanced private equity oversight.
The board also approved a revision to the company’s Employee Stock Option Scheme 2026, trimming the total option pool from 13,475,000 to 13,098,000 options while retaining other previously disclosed terms. The recalibrated ESOP structure suggests a more measured equity incentive framework, potentially limiting dilution for existing shareholders while still aligning employee interests with long-term performance.
More about Viyash Scientific
Viyash Scientific Limited, formerly known as Sequent Scientific Limited, is an India-based listed company in the scientific and pharmaceutical space, with its registered office in Hyderabad, Telangana. The company’s shares trade on both BSE and the National Stock Exchange of India under the scrip code 512529 and ticker VIYASH, reflecting its presence in the domestic capital markets.
Average Trading Volume: 34,439
Technical Sentiment Signal: Strong Buy
Current Market Cap: 90.47B INR
For a thorough assessment of VIYASH stock, go to TipRanks’ Stock Analysis page.